This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
- Kemper Kelly, MT(ASCP)⇑
- Carrie Cocklin, M.D.
- Address for Correspondence: Kemper Kelly, MT(ASCP), 88th DTS/SGQC, 4881 Sugar Maple Dr, Wright-Patterson AFB, OH 45433, kemper.kelly{at}wpafb.af.mil, 937-257-9375, (fax)937-257-9342.
Abstract
Renal cell carcinoma (RCC) affects patients by proliferating in the renal tubules, resulting in renal failure and concomitant urinalysis findings of blood, protein, casts, and abnormal cells in the urine. If untreated, it can spread to the lymph nodes, liver, and lungs. There is currently no proven tumor marker for RCC. The clinical case reported here describes the clinical laboratory findings in a patient with 2 common co-morbidities (metabolic syndrome and alcoholism), who was found to have metastatic renal cell carcinoma at autopsy. Understanding the clinical chemistry of metastatic carcinoma in the presence of common co-morbidities is important for earlier diagnosis and treatment of patients who are most likely to develop these conditions.
ABBREVIATIONS: ALP= Alkaline phosphatase, Hct= Hematocrit, AST= Aspartate aminotransferase, MCV= Mean corpuscular volume, ALT= Alanine transaminase, MCHC= Mean corpuscular hemoglobin concentration, BUN= Blood urea nitrogen, RDW= Red blood cell distribution width, GFR= Glomerular filtration rate, PLT= Platelet, WBC= White Blood Cells, INR= International normalized ratio, aPTT= activated Partial thromboplastin time, GGT= Gamma-glutamyl transferase.
- INDEX TERMS
- RCC
- renal cancer
- CAIX
- carbonic anhydrase
- © Copyright 2010 American Society for Clinical Laboratory Science Inc. All rights reserved.